Cargando…
Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis
AIMS : Fibroblast growth factor (FGF) 21, a key regulator of energy metabolism, is currently evaluated in humans for treatment of type 2 diabetes and non-alcoholic steatohepatitis. However, the effects of FGF21 on cardiovascular benefit, particularly on lipoprotein metabolism in relation to atheroge...
Autores principales: | Liu, Cong, Schönke, Milena, Zhou, Enchen, Li, Zhuang, Kooijman, Sander, Boon, Mariëtte R, Larsson, Mikael, Wallenius, Kristina, Dekker, Niek, Barlind, Louise, Peng, Xiao-Rong, Wang, Yanan, Rensen, Patrick C N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803070/ https://www.ncbi.nlm.nih.gov/pubmed/33693480 http://dx.doi.org/10.1093/cvr/cvab076 |
Ejemplares similares
-
FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis
por: Liu, Cong, et al.
Publicado: (2023) -
Role of thermogenic adipose tissue in lipid metabolism and atherosclerotic cardiovascular disease: lessons from studies in mice and humans
por: Ying, Zhixiong, et al.
Publicado: (2022) -
Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice
por: Bartesaghi, Stefano, et al.
Publicado: (2022) -
Mild Exercise Does Not Prevent Atherosclerosis in APOE*3‐Leiden.CETP Mice or Improve Lipoprotein Profile of Men with Obesity
por: In het Panhuis, Wietse, et al.
Publicado: (2020) -
Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidaemia and atherosclerosis development
por: Zhou, Enchen, et al.
Publicado: (2020)